Oxford Biomedica plc (LON:OXB - Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 352.05 ($4.78) and traded as low as GBX 332.50 ($4.51). Oxford Biomedica shares last traded at GBX 337.50 ($4.58), with a volume of 125,922 shares trading hands.
Oxford Biomedica Stock Down 2.4%
The company has a current ratio of 2.35, a quick ratio of 1.67 and a debt-to-equity ratio of 166.48. The stock has a market cap of £344.42 million, a P/E ratio of -2.41 and a beta of 1.09. The company's 50 day moving average price is GBX 301.55 and its two-hundred day moving average price is GBX 350.74.
Oxford Biomedica (LON:OXB - Get Free Report) last issued its quarterly earnings data on Wednesday, April 9th. The biopharmaceutical company reported GBX (41.75) (($0.57)) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative net margin of 145.98% and a negative return on equity of 202.50%. Equities analysts forecast that Oxford Biomedica plc will post -31.0799998 earnings per share for the current year.
Oxford Biomedica Company Profile
(
Get Free Report)
Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.
Featured Stories
Before you consider Oxford Biomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.
While Oxford Biomedica currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
